In the latest trading session, 0.73 million Esperion Therapeutics Inc. (NASDAQ:ESPR) shares changed hands as the company’s beta touched 1.02. With the company’s most recent per share price at $1.91 changed hands at -$0.05 or -2.50% at last look, the market valuation stands at $362.06M. ESPR’s current price is a discount, trading about -78.01% off its 52-week high of $3.40. The share price had its 52-week low at $0.70, which suggests the last value was 63.35% up since then. When we look at Esperion Therapeutics Inc.’s average trading volume, we note the 10-day average is 5.53 million shares, with the 3-month average coming to 7.32 million.
Analysts gave the Esperion Therapeutics Inc. (ESPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ESPR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Esperion Therapeutics Inc.’s EPS for the current quarter is expected to be -0.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Instantly ESPR was in red as seen in intraday trades today. With action 3.86%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -36.09%, with the 5-day performance at 3.86% in the green. However, in the 30-day time frame, Esperion Therapeutics Inc. (NASDAQ:ESPR) is -20.04% down. Looking at the short shares, we see there were 38.14 million shares sold at short interest cover period of 6.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 88.06% from its recent market value. According to analyst projections, ESPR’s forecast low is 12 with 20 as the target high. To hit the forecast high, the stock’s price needs a -947.12% plunge from its current level, while the stock would need to soar -528.27% for it to hit the projected low.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Data shows that the Esperion Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -28.96% over the past 6 months, a 98.03% in annual growth rate that is considerably higher than the industry average of 19.30%. Year-over-year growth is forecast to reach 196.30% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 53.16M. 6 analysts are of the opinion that Esperion Therapeutics Inc.’s revenue for the current quarter will be 63.18M. The estimates for the next quarter sales put growth at 95.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 23.09%. The 2024 estimates are for Esperion Therapeutics Inc. earnings to increase by 88.18%, but the outlook for the next 5-year period is at 16.90% per year.
ESPR Dividends
Esperion Therapeutics Inc. is expected to release its next quarterly earnings report on 2024-Nov-05.
Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.50% of Esperion Therapeutics Inc. shares while 70.55% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 70.91%. There are 70.55% institutions holding the Esperion Therapeutics Inc. stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-03-31, the company held 12.196% of the shares, roughly 13.71 million ESPR shares worth $36.74 million.
BELLEVUE GROUP AG holds the second largest percentage of outstanding shares, with 8.8468% or 9.94 million shares worth $26.65 million as of 2024-03-31.
Among Mutual Funds, the top two as of Mar 31, 2024 were Vanguard Total Stock Market Index Fund and Wasatch Ultra Growth Fund. With 5.36 shares estimated at $10.19 million under it, the former controlled 2.73% of total outstanding shares. On the other hand, Wasatch Ultra Growth Fund held about 2.33% of the shares, roughly 4.57 shares worth around $8.69 million.
